Low-Dose Nivolumab Plus AVD As Front-Line Therapy for Classical Hodgkin's Lymphoma: Preliminary Results of a Phase 2 Trial

被引：0
作者：
Mateos, Antonio Vega [1 ]
Alfaro, Hector Alejandro Vaquera [1 ]
Vasquez, Ana Cristina Tejada [1 ]
Lopez-Garcia, Yadith Karina [1 ]
Garcia-Salas, Gerardo [1 ]
Cantu, Olga [1 ]
Gomez-De Leon, Andres [1 ]
Gomez-Almaguer, David [1 ]
Tarin-Arzaga, Luz [1 ]
Gutierrez-Aguirre, Cesar Homero [1 ]
Colunga-Pedraza, Perla R. [1 ]
机构：
[1] Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose Eleuterio Gonzalez, Serv Hematol, Monterrey, Mexico
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-208831
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1665 / 1666
页数：2
相关论文
共 50 条
  • [41] Interim Analysis Results of a Phase 2 Trial of Low-Dose Radiation Therapy for Palliation of Diffuse Large B-Cell Lymphoma
    Furlan, C.
    Bulian, P.
    Spina, M.
    Michieli, M.
    Ermacora, A.
    Tirelli, U.
    Trovo, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S80 - S80
  • [42] Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML).
    Cashen, Amanda
    Schiller, Gary J.
    Larsen, Julie S.
    Cullen, Michael T., Jr.
    DiPersio, John F.
    BLOOD, 2006, 108 (11) : 561A - 562A
  • [43] Primary results from Japanese phase I study of pembrolizumab plus chemotherapy as front-line therapy for advanced NSCLC
    Kurata, Takayasu
    Nakagawa, Kazuhiko
    Satouchi, Miyako
    Seto, Takashi
    Sawada, Takeshi
    Han, Shi Rong
    Noguchi, Kazuo
    Shimamoto, Takashi
    Nogami, Naoyuki
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial
    Broeckelmann, Paul J.
    Buehnen, Ina
    Herhaus, Peter
    Meissner, Julia
    Trautmann-Grill, Karolin
    Mueller, Horst
    Fuchs, Michael
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    Behringer, Karolin
    BLOOD, 2023, 142
  • [45] Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study
    Picardi, Marco
    Giordano, Claudia
    Pugliese, Novella
    Esposito, Maria
    Fatigati, Melania
    Muriano, Francesco
    Rascato, Maria G.
    Pepa, Roberta Della
    D'Ambrosio, Alessandro
    Vigliar, Elena
    Troncone, Giancarlo
    Russo, Daniela
    Mascolo, Massimo
    Esposito, Giovanni
    Prastaro, Mariella
    Esposito, Roberta
    Tocchetti, Carlo G.
    Fonti, Rosa
    Mainolfi, Ciro
    Del Vecchio, Silvana
    Pane, Fabrizio
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (05) : 847 - 860
  • [46] Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)
    Romualdo Barroso-Sousa
    Jorge Gomez Tejeda Zanudo
    Tianyu Li
    Sangeetha M. Reddy
    Leisha A. Emens
    Thomas M. Kuntz
    Carolina Alves Costa Silva
    Saud H. AlDubayan
    Hoyin Chu
    Beth Overmoyer
    Paulina Lange
    Molly K. DiLullo
    Meagan Montesion
    Julie Kasparian
    Melissa E. Hughes
    Victoria Attaya
    Ameer Basta
    Nancy U. Lin
    Nabihah Tayob
    Rinath Jeselsohn
    Elizabeth A. Mittendorf
    Sara M. Tolaney
    Nature Communications, 16 (1)
  • [47] Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML)
    Cashen, Amanda F.
    Schiller, Gary J.
    O'Donnell, Margaret R.
    Larsen, Julie S.
    Baranwal, Akhil
    Cullen, Michael T.
    DiPersio, John F.
    BLOOD, 2008, 112 (11) : 210 - 210
  • [48] A phase II trial of front-line double high dose chemotherapy (HDCT) with DICEP then BEAM and autologous stem cell transplantation (ASCT) as induction therapy for poor prognosis aggressive non-Hodgkin's lymphoma (NHL).
    Stewart, DA
    Glück, S
    Chaudhry, A
    Morris, D
    Parameswaran, R
    Brown, C
    Balogh, A
    Valentine, K
    Jones, A
    Ruether, B
    Blahey, W
    Thaell, T
    Russell, JA
    BLOOD, 2002, 100 (11) : 645A - 645A
  • [49] Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
    Moskowitz, Alison J.
    Shah, Gunjan
    Schoder, Heiko
    Ganesan, Nivetha
    Hancock, Helen
    Davey, Theresa
    Sohail, Samia
    Santarosa, Alayna
    Pomerantz, Lauren
    Jarjies, Christine
    Galasso, Natasha
    Neuman, Rachel
    Kumar, Anita
    Lahoud, Oscar B.
    Batlevi, Connie Lee
    Hamlin, Paul A.
    Straus, David J.
    Rodriguez-Rivera, Ildefonso
    Owens, Colette
    Caron, Philip
    Intlekofer, Andrew M.
    Hamilton, Audrey
    Horwitz, Steven M.
    Falchi, Lorenzo
    Joffe, Erel
    Palomba, Maria Lia
    Noy, Ariela
    Matasar, Matthew J.
    Pongas, Georgios
    Vardhana, Santosha
    von Keudell, Gottfried R.
    Yahalom, Joachim
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 14 - 15
  • [50] Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
    Moskowitz, Alison J.
    Shah, Gunjan
    Schoder, Heiko
    Ganesan, Nivetha
    Hancock, Helen
    Davey, Theresa
    Sohail, Samia
    Santarosa, Alayna
    Pomerantz, Lauren
    Jarjies, Christine
    Galasso, Natasha
    Neuman, Rachel
    Kumar, Anita
    Lahoud, Oscar B.
    Batlevi, Connie Lee
    Hamlin, Paul A.
    Straus, David J.
    Rodriguez-Rivera, Ildefonso
    Owens, Colette
    Caron, Philip
    Intlekofer, Andrew M.
    Hamilton, Audrey
    Horwitz, Steven M.
    Falchi, Lorenzo
    Joffe, Erel
    Palomba, Maria Lia
    Noy, Ariela
    Matasar, Matthew J.
    Pongas, Georgios
    Vardhana, Santosha
    von Keudell, Gottfried R.
    Yahalom, Joachim
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    BLOOD, 2020, 136
12345